Walthausen & Co. LLC Cuts Position in NeoGenomics, Inc. (NEO)

Walthausen & Co. LLC cut its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 15.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,810 shares of the medical research company’s stock after selling 14,240 shares during the period. Walthausen & Co. LLC owned about 0.08% of NeoGenomics worth $981,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Ruggie Capital Group raised its stake in NeoGenomics by 74.1% in the fourth quarter. Ruggie Capital Group now owns 2,350 shares of the medical research company’s stock valued at $30,000 after buying an additional 1,000 shares in the last quarter. CWM LLC acquired a new stake in NeoGenomics in the fourth quarter valued at $30,000. First Quadrant L P CA acquired a new stake in NeoGenomics in the fourth quarter valued at $65,000. Quantamental Technologies LLC acquired a new stake in NeoGenomics in the fourth quarter valued at $76,000. Finally, Bessemer Group Inc. acquired a new stake in NeoGenomics in the fourth quarter valued at $78,000. Institutional investors own 77.00% of the company’s stock.

In other NeoGenomics news, EVP Steven C. Jones sold 14,621 shares of NeoGenomics stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $19.24, for a total value of $281,308.04. Following the sale, the executive vice president now owns 241,815 shares of the company’s stock, valued at approximately $4,652,520.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jennifer Balliet sold 14,000 shares of NeoGenomics stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $19.09, for a total value of $267,260.00. Following the completion of the sale, the vice president now directly owns 40,000 shares in the company, valued at approximately $763,600. The disclosure for this sale can be found here. In the last three months, insiders have sold 263,524 shares of company stock worth $5,019,496. Corporate insiders own 12.20% of the company’s stock.

A number of research firms have recently commented on NEO. BidaskClub cut NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. CIBC upgraded NeoGenomics from a “neutral” rating to an “outperform” rating and cut their target price for the stock from $18.00 to $15.00 in a research report on Tuesday, March 12th. Zacks Investment Research cut NeoGenomics from a “buy” rating to a “hold” rating in a research report on Saturday, March 2nd. Needham & Company LLC began coverage on NeoGenomics in a research report on Thursday, January 3rd. They set a “buy” rating and a $14.00 target price on the stock. Finally, ValuEngine upgraded NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $19.55.

Shares of NASDAQ NEO traded up $0.09 during midday trading on Friday, reaching $19.66. 677,530 shares of the company were exchanged, compared to its average volume of 713,607. The company has a quick ratio of 1.56, a current ratio of 1.70 and a debt-to-equity ratio of 0.31. NeoGenomics, Inc. has a 1 year low of $9.08 and a 1 year high of $22.17. The firm has a market cap of $1.86 billion, a P/E ratio of 151.23 and a beta of 0.93.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, February 19th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.02. NeoGenomics had a return on equity of 2.25% and a net margin of 0.95%. The firm had revenue of $76.50 million for the quarter, compared to analyst estimates of $71.29 million. During the same quarter last year, the company posted $0.05 earnings per share. The business’s revenue was up 24.6% on a year-over-year basis. As a group, analysts anticipate that NeoGenomics, Inc. will post 0.18 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/21/walthausen-co-llc-cuts-holdings-in-neogenomics-inc-neo.html.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Recommended Story: What are the benefits of investing in REITs?

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.